Filing identity and reporting period
Important metadata discrepancy: The supplied filing is AspenBio Pharma, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2012—not a Riot Platforms, Inc. filing. This summary reflects the supplied AspenBio filing.
Business context and financial results
AspenBio reported minimal product sales while focusing development resources on AppyScore, its acute appendicitis diagnostic, and animal-health products. The company reported recurring losses and negative operating cash flow.
| Metric | Three months ended June 30, 2012 | Six months ended June 30, 2012 | Comparable 2011 period |
|---|---|---|---|
| Sales | $27,241 | $34,516 | $55,322 quarter; $152,638 six months |
| Operating loss | $2.25 million | $4.12 million | $2.75 million quarter; $5.52 million six months |
| Net loss | $2.31 million | $4.25 million | $2.79 million quarter; $5.59 million six months |
| Basic and diluted loss per share | $1.19 | $2.39 | $2.08 quarter; $4.17 six months |
| Gross margin | Approximately 100% | Approximately 100% | 95% quarter; 90% six months |
Six-month operating expenses were $4.16 million, including $2.60 million of selling, general and administrative expense and $1.56 million of research and development expense. Net interest expense was $126,733 for the six-month period.
Cash, liquidity, and debt
- At June 30, 2012, cash and cash equivalents were $10.95 million and short-term investments were $210,000; together, approximately $11.16 million. Working capital was $9.35 million.
- Six-month operating cash use was $3.06 million; investing activities provided $740,000 and financing activities provided $10.31 million. Cash ended the period at $10.95 million, versus $2.97 million at year-end 2011.
- Notes and other obligations totaled $3.27 million, including $900,000 classified as current. The commercial-bank mortgage portion has an estimated $1.58 million principal balance due in July 2013; the company also owed $782,000 under the Novartis termination agreement.
- The June public offering generated $12.2 million gross and approximately $10.94 million net proceeds after $1.26 million in fees and expenses. The company issued 6.1 million shares at $2.00 each and granted the underwriter warrants and an option to purchase additional shares.
Changes versus prior periods
- Six-month sales fell 77% year over year, which management attributed primarily to suspending antigen production in 2010. The company recognized no Novartis license revenue in 2012 after terminating that agreement in 2011.
- Six-month SG&A declined 12% and R&D declined 43% year over year. Lower personnel, stock-based compensation, and development activity contributed to the reductions; AppyScore work included a pilot trial completed in 2011.
- Six-month net loss narrowed to $4.25 million from $5.59 million, while operating cash use improved to $3.06 million from $4.35 million.
- Shares outstanding increased substantially following the offering. A one-for-six reverse stock split took effect June 20, 2012; historical share and per-share figures in the filing reflect the split.
Outlook, risks, and unusual items
- Management expected continued near-term losses, potentially significant, but believed available working capital would cover estimated cash needs through the remainder of 2012. It was seeking additional financing and warned that a failure to raise capital could require reduced R&D or cessation of operations. The filing describes these conditions as going-concern risks.
- Management’s priorities included advancing AppyScore toward FDA clearance, monetizing the animal-health business, pursuing partnerships or licenses, raising capital, and controlling costs. Expected 2012 capital expenditures were approximately $50,000–$100,000.
- In July 2012, AspenBio entered a conditional exclusive animal-health license with Ceva. Consideration includes $1.02 million in license fees, up to $4 million in potential milestones, and low-double-digit royalties. Future payments are conditional on a bovine proof-of-concept study expected by September 30, 2012; Ceva may terminate if the condition is not met. The first $204,000 installment was recorded as deferred revenue at June 30.
- Three securities-related matters concerning AppyScore were disclosed: two motions to dismiss were pending, and a shareholder derivative action remained stayed. The company said it intended to defend the claims.
- Sales and receivables were concentrated among a small number of customers. The filing reported no material change to the risk factors in the prior annual report.
Important facts for investors to verify
- Confirm the issuer and filing: the supplied document identifies AspenBio Pharma, not Riot Platforms.
- Verify cash burn, financing needs, and whether subsequent capital was obtained; management’s stated liquidity horizon was only through the end of 2012.
- Check whether the Ceva proof-of-concept condition was met and whether the license fees, milestones, or royalties became payable.
- Review AppyScore’s FDA and development status, as well as subsequent developments in the disclosed litigation.
- Assess the July 2013 mortgage maturity, other debt payments, and the effects of the June offering and reverse split on dilution and share counts.